Table 4.

Proportion of PD-L1-expressing tumor cells in early-stage vs. advanced-stage NSCLC regarding co-occurring actionable mutations and gene rearrangements.

		Stage I–IIIA	Stage IIIB–IV	p-Value
	PD-L1	N (%)	N (%)
EGFR	TPS ≥ 1% < 50%	18/70 (25.7%)	25/75 (33.3%)	0.4112
	TPS ≥ 50%	5/70 (7.1%)	9/75 (12%)	0.4042
KRAS G12C	TPS ≥ 1% < 50%	60/102 (58.8%)	68/107 (63.6%)	0.5760
	TPS ≥ 50%	25/102 (24.5%)	38/107 (35.5%)	0.1136
BRAF V600E	TPS ≥ 1% < 50%	6/10 (60%)	14/16 (87.5%)	0.1627
	TPS ≥ 50%	2/10 (20%)	6/16 (42.9%)	0.4198
ERBB2	TPS ≥ 1% < 50%	2/5 (40%)	3/12 (25%)
	TPS ≥ 50%	0/5 (0%)	1/12 (8.3%)
ALK	TPS ≥ 1% < 50%	2/7 (28.6%)	5/14 (35.7%)
	TPS ≥ 50%	0/7 (0%)	1/14 (7.1%)
ROS1	TPS ≥ 1% < 50%	1/1 (100.0%)	2/4 (50%)
	TPS ≥ 50%	0/0 (0%)	2/4 (50%)
RET	TPS ≥ 1% < 50%	3/4 (75%)	3/4 (75%)
	TPS ≥ 50%	1/4 (25%)	2/4 (50%)
METExon14skip	TPS ≥ 1% < 50%	10/19 (52.6%)	21/22 (95.5%)	0.0024
	TPS ≥ 50%	5/19 (26.3%)	15/22 (68.2%)	0.0122